01332nas a2200349   4500000000100000008004100001260001300042653001500055653001000070653000900080653002200089653001400111653001000125653001200135653001100147653001400158653001100172653001200183653000900195653001600204653002200220653001800242100001400260700001300274700001500287245005700302300000900359490000700368050003200375520056100407022001400968       1981                            d  c1981 Jan10aAdolescent10aAdult10aAged10aAnemia, Hemolytic10aBilirubin10aChild10aDapsone10aFemale10aHemolysis10aHumans10aleprosy10aMale10aMiddle Aged10aOsmotic Fragility10aReticulocytes1 aMenezes S1 aRege V L1 aSehgal V N00aDapsone haemolysis in leprosy. A preliminary report.  a63-90 v53  aInfolep Library - available3 a<p>Fifty one patients with leprosy from the Urban Leprosy Centre, attached to the Department of Dermatology and Venereology, Goa Medical College on treatment with Dapsone were studied from the point of view of development of haemolysis related to the drug. The findings are described and discussed. Anaemia developed in 60.7 percent of the patients during the course of treatment. It was mild and well compensated. The haemolytic effect of dapsone was related to the dose and duration of the treatment, being more manifested in doses above 50 mg daily.</p>  a0024-1024